摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-fluoro-4-(2-(1-methyl-1H-imidazol-2-yl)thieno[3,2-b]pypyridin-7-yloxy)benzenamine | 875340-30-0

中文名称
——
中文别名
——
英文名称
3-fluoro-4-(2-(1-methyl-1H-imidazol-2-yl)thieno[3,2-b]pypyridin-7-yloxy)benzenamine
英文别名
3-Fluoro-4-(2-(1-methyl-1H-imidazol-2-yl)thieno[3,2-b]pyridin-7-yloxy)benzenamine;3-fluoro-4-{[2-(1-methyl-1H-2-imidazolyl)thieno[3,2-b]pyridin-7-yl]oxy}aniline;3-fluoro-4-[2-(1-methylimidazol-2-yl)thieno[3,2-b]pyridin-7-yl]oxyaniline
3-fluoro-4-(2-(1-methyl-1H-imidazol-2-yl)thieno[3,2-b]pypyridin-7-yloxy)benzenamine化学式
CAS
875340-30-0
化学式
C17H13FN4OS
mdl
——
分子量
340.381
InChiKey
BINMGRBJWNEAJX-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.7
  • 重原子数:
    24
  • 可旋转键数:
    3
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.06
  • 拓扑面积:
    94.2
  • 氢给体数:
    1
  • 氢受体数:
    6

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    3-fluoro-4-(2-(1-methyl-1H-imidazol-2-yl)thieno[3,2-b]pypyridin-7-yloxy)benzenamine3-苯胺基-3-羰基丙酸 在 (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate 、 N,N-二异丙基乙胺 作用下, 以 N,N-二甲基甲酰胺 为溶剂, 反应 2.0h, 以9%的产率得到N1-(3-Fluoro-4-(2-(1-methyl-1H-imidazol-2-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)-N3-phenylmalonamide
    参考文献:
    名称:
    Inhibitors of VEGF receptor and HGF receptor signaling
    摘要:
    该发明涉及抑制VEGF受体信号和HGF受体信号。该发明提供了抑制VEGF受体信号和HGF受体信号的化合物和方法。该发明还提供了治疗细胞增殖性疾病和病况的组合物和方法。
    公开号:
    US20070004675A1
  • 作为产物:
    描述:
    7-(2-Fluoro-4-nitrophenoxy)-2-(1-methyl-1H-imidazol-2-yl)thieno[3,2-b]pyridine 在 nickel dichloride sodium tetrahydroborate 、 盐酸 作用下, 以 四氢呋喃甲醇 为溶剂, 反应 0.5h, 以52%的产率得到3-fluoro-4-(2-(1-methyl-1H-imidazol-2-yl)thieno[3,2-b]pypyridin-7-yloxy)benzenamine
    参考文献:
    名称:
    Inhibitors of VEGF receptor and HGF receptor signaling
    摘要:
    该发明涉及抑制VEGF受体信号和HGF受体信号。该发明提供了抑制VEGF受体信号和HGF受体信号的化合物和方法。该发明还提供了治疗细胞增殖性疾病和病况的组合物和方法。
    公开号:
    US20070004675A1
点击查看最新优质反应信息

文献信息

  • Inhibitors of VEGF receptor and HGF receptor signaling
    申请人:Saavedra Mario Oscar
    公开号:US20070004675A1
    公开(公告)日:2007-01-04
    The invention relates to the inhibition of VEGF receptor signaling and HGF receptor signaling. The invention provides compounds and methods for inhibiting VEGF receptor signaling and HGF receptor signaling. The invention also provides compositions and methods for treating cell proliferative diseases and conditions
    该发明涉及抑制VEGF受体信号和HGF受体信号。该发明提供了抑制VEGF受体信号和HGF受体信号的化合物和方法。该发明还提供了治疗细胞增殖性疾病和病况的组合物和方法。
  • [EN] INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING<br/>[FR] INHIBITEURS DE SIGNALISATION DE RECEPTEUR DU FACTEUR DE CROISSANCE ENDOTHELIALE (VEGF) ET DE RECEPTEUR DE FACTEUR DE CROISSANCE DES HEPATOCYTES (HGF)
    申请人:METHYLGENE INC
    公开号:WO2006010264A1
    公开(公告)日:2006-02-02
    The invention relates to the inhibition of vascular endothelial growth factor (VEGF) receptor signaling and hepatocyte growth factor (HGF) receptor signaling. The invention provides compounds and methods for inhibiting VEGF receptor signaling and HGF receptor signaling. The invention also provides compositions and methods for treating cell proliferative diseases and conditions
    该发明涉及抑制血管内皮生长因子(VEGF)受体信号和肝细胞生长因子(HGF)受体信号的方法。该发明提供了抑制VEGF受体信号和HGF受体信号的化合物和方法。该发明还提供了治疗细胞增殖性疾病和症状的组合物和方法。
  • INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING
    申请人:Saavedra Mario Oscar
    公开号:US20060287343A1
    公开(公告)日:2006-12-21
    The invention relates to the inhibition of VEGF receptor signaling and HGF receptor signaling. The invention provides compounds and methods for inhibiting VEGF receptor signaling and HGF receptor signaling. The invention also provides compositions and methods for treating cell proliferative diseases and conditions
    本发明涉及抑制VEGF受体信号和HGF受体信号的方法。本发明提供了抑制VEGF受体信号和HGF受体信号的化合物和方法。本发明还提供了用于治疗细胞增殖性疾病和病状的组合物和方法。
  • INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY
    申请人:Saavedra Mario Oscar
    公开号:US20080064718A1
    公开(公告)日:2008-03-13
    This invention relates to compounds that inhibit protein tyrosine kinase activity. In particular the invention relates to compounds that inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signaling, for example, the inhibition of VEGF receptor signaling and HGF receptor signaling. More particularly, the invention relates to compounds, compositions and methods for the inhibition of VEGF receptor signaling and HGF receptor signaling. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.
    本发明涉及抑制蛋白酪氨酸激酶活性的化合物。特别是,本发明涉及抑制生长因子受体蛋白酪氨酸激酶活性的化合物,从而抑制受体信号传导,例如抑制VEGF受体信号和HGF受体信号的传导。更具体地,本发明涉及用于抑制VEGF受体信号和HGF受体信号的化合物、组合物和方法。本发明还提供了用于治疗细胞增殖性疾病和病状的组合物和方法。
  • THIENOPYRIDINE DERIVATIVE, OR QUINOLINE DERIVATIVE, OR QUINAZOLINE DERIVATIVE, HAVING c-MET AUTOPHOSPHORYLATION INHIBITING POTENCY
    申请人:Kubo Kazuo
    公开号:US20090270391A1
    公开(公告)日:2009-10-29
    An objective of the present invention is to provide compounds having antitumor activity. According to the present invention, there is provided compounds represented by formula (I) and pharmaceutically acceptable salts thereof, and solvates thereof: wherein R 1 represents H or a substitutable unsaturated five- or six-membered heterocyclic ring; R 2 represents H; X represents CH or N; Z represents O or S; E is absent or represents halogen, alkyl, or alkoxy; J represents S or O; and T represents phenyl, an unsaturated five- or six-membered heterocyclic ring, an unsaturated nine- or ten-membered bicyclic carbocyclic ring or heterocyclic ring.
    本发明的目标是提供具有抗肿瘤活性的化合物。根据本发明,提供了由公式(I)表示的化合物及其药学上可接受的盐和溶剂化物:其中,R1代表H或可取代的不饱和五元或六元杂环环;R2代表H;X代表CH或N;Z代表O或S;E不存在或代表卤素,烷基或烷氧基;J代表S或O;T代表苯基,不饱和五元或六元杂环环,不饱和九元或十元双环碳环或杂环环。
查看更多